BABarbara Agosti

Barbara Agosti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Barbara Agosti has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Defining and Predicting Inadequate Weight Response to Oral Semaglutide

    by Antonio Maria Labate, Provvidenza Villari, Elena Cimino, Laura Giacomelli, Oladayo Adigun Oladeji, Barbara Agosti

    Background: Oral semaglutide produces substantial average weight loss, but the term non-responder combines clinically different situations. Failure to cross a numerical threshold may reflect limited treatment exposure, intolerance, a slow trajectory or persistently inadequate efficacy. Identifying these situations is particularly important when evidence from diabetes doses is applied to oral obesity treatment. Objective: To critically examine definitions of inadequate weight response to oral semaglutide and assess whether baseline characteristics or early treatment patterns identify patients likely to derive less weight benefit. Methods: A narrative synthesis drew on searches of PubMed, Embase, Web of Science and CENTRAL, supplemented by primary trial appendices and conference materials. Evidence was interpreted separately by oral dose, diabetes status, follow-up, analysis population and publication type. Observed responder counts were distinguished from model-based estimates. No quantitative pooling was performed. Results: The apparent frequency of weight loss below 5% varied substantially with population, dose and denominator. At the end of OASIS 4, 40/192 participants with observed in-trial measurements and 20/157 with on-treatment measurements remained below 5% loss. These proportions do not establish biological resistance. Baseline sex and body weight showed exploratory signals in OASIS 1, whereas age, BMI, diabetes duration and baseline HbA1c did not consistently distinguish weight response across studies. An OASIS 4 post hoc analysis associated early weight loss with subsequent trajectories, but participants below 5% loss at week 16 still achieved a mean 7.0% reduction at week 64. Behavioral and exposure models remain exploratory. Conclusions: Current evidence supports a time-dependent, treatment-specific assessment of inadequate weight response rather than a fixed baseline non-responder phenotype. Early trajectories inform expectations but do not validate an automatic stopping rule. Persistent low weight response should be described alongside achieved dose, administration, persistence, tolerability and other treatment outcomes.

  • Open Access

    Efficacy and Safety of Oral Small-Molecule (Non-Peptide) GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity: A Systematic Review of the Complete Orforglipron and Danuglipron Clinical Development Programs

    by Antonio Maria Labate, Provvidenza Villari, Elena Cimino, Laura Giacomelli, Oladayo Adigun Oladeji, Barbara Agosti

    Background/Objectives: Orforglipron and danuglipron are the two most clinically advanced oral small-molecule (non-peptide) GLP-1 receptor agonists, sharing a common mechanism of action but markedly different regulatory outcomes — approval versus discontinuation. No existing review synthesizes their complete registrational evidence. Methods: We systematically searched PubMed, Embase, Cochrane CENTRAL, and Web of Science (inception to September 2026; PROSPERO-registered protocol) for phase 2/3 randomized controlled trials of orforglipron or danuglipron in adults with type 2 diabetes and/or obesity. Risk of bias was assessed with Cochrane RoB 2. Comparable trials were pooled using random-effects meta-analysis; clinically heterogeneous or non-comparable trials were synthesized narratively. Results: Of 505 records identified (286 after deduplication), 13 phase 2/3 randomized controlled trials met the registered eligibility criteria (10 orforglipron, 3 danuglipron); a further 17 reports (phase 1, mechanistic, or post hoc analyses of these trials) were retained only as contextual evidence. Of the 13 eligible trials, 9 (6 orforglipron phase 3, 3 danuglipron phase 2; N=9,693) were included in the quantitative synthesis, of which subsets sharing a common comparator were combined by random-effects meta-analysis (3 trials for HbA1c, 2 for body weight in type 2 diabetes); the remainder are reported as standalone estimates. Orforglipron produced a pooled HbA1c reduction of −1.14 percentage points versus placebo (95% CI −1.25 to −1.02; I²=0%) and superior glycemic control versus dapagliflozin and oral semaglutide. Weight loss varied by population: −9.10% in obesity without diabetes (single trial) and a pooled −6.54% in type 2 diabetes (95% CI −7.96 to −5.11; I²=49.8%, explained by background therapy). No hepatic safety signal was observed across 11,220 pooled orforglipron participants. Danuglipron showed comparable glycemic and weight efficacy but substantially higher, dose-dependent discontinuation (up to 72.7% in one arm), and its development was discontinued after a probable drug-induced liver injury case identified in a later, unpublished study. Conclusions: Despite a shared molecular target, orforglipron and danuglipron followed divergent clinical trajectories driven by differences in dosing regimen, tolerability, and hepatic safety rather than by pharmacodynamic efficacy, which was broadly comparable between the two molecules. These findings underscore that efficacy alone is an incomplete predictor of clinical success for oral small-molecule GLP-1 receptor agonists.

  • Open Access

    Artificial Intelligence in Non-Insulin-Treated Type 2 Diabetes: From Reactive Management to Anticipatory Care

    by Antonio Maria Labate, Elena Cimino, Laura Giacomelli, Stefano Ettori, Oladayo Adigun Oladeji, Barbara Agosti

    Type 2 diabetes mellitus is a highly prevalent, heterogeneous, and progressive chronic disease. In a large proportion of patients, management is based for many years on lifestyle intervention and non-insulin glucose-lowering therapies. This long pre-insulin phase represents a crucial clinical window, in which timely recognition of metabolic deterioration, therapeutic inertia, treatment response, and individual risk trajectories may substantially influence long-term outcomes. However, routine care is still frequently based on intermittent assessments, delayed treatment adaptation, and limited integration of clinical, biochemical, behavioral, and digital data. Artificial intelligence may offer a clinically relevant opportunity to move from reactive management to anticipatory care in non-insulin-treated type 2 diabetes. Rather than replacing clinical judgment or automating treatment decisions, artificial intelligence can support clinicians by identifying hidden patterns, predicting metabolic worsening, stratifying risk, improving the interpretation of glucose data, and personalizing follow-up intensity and therapeutic timing. In this setting, its most meaningful role may be to reduce the silent interval between early deterioration and clinical action. This narrative review discusses the rationale, current applications, near-future scenarios, and implementation barriers of artificial intelligence in non-insulin-treated type 2 diabetes. Particular attention is given to advanced interpretation of glycemic data, clinical decision support, prediction of treatment failure, remote monitoring, and the potential integration of multidimensional data into more precise and timely care pathways. The review also emphasizes the need for explainable, clinically validated, equitable, and ethically governed artificial intelligence tools that can be realistically embedded into everyday diabetology practice.


  • Open Access

    Molecular Pathways of Cardiometabolic Residual Risk in Type 2 Diabetes: Insulin Resistance, Metaflammation, and Liver–Kidney–Vascular Crosstalk

    by Antonio Maria Labate, Elena Cimino, Laura Giacomelli, Stefano Ettori, Oladayo Adigun Oladeji, Barbara Agosti

    Cardiometabolic residual risk in type 2 diabetes mellitus (T2D) persists despite major advances in glucose-lowering therapy, lipid management, blood pressure control, weight reduction, and organ-protective strategies. This residual burden should not be interpreted solely as the consequence of incomplete achievement of conventional therapeutic targets, but rather as the clinical expression of persistent molecular activity involving multiple interconnected organs and pathways. Insulin resistance, metaflammation, oxidative stress, mitochondrial dysfunction, lipotoxicity, endothelial impairment, hepatic metabolic dysregulation, renal inflammation, fibrotic remodeling, and metabolic memory interact within a dynamic network linking adipose tissue, liver, kidney, immune cells, and vasculature. In this review, we discuss the biochemical and molecular drivers of cardiometabolic residual risk in T2D, with particular emphasis on impaired insulin receptor substrate/PI3K/Akt signaling, stress-kinase activation, NLRP3 inflammasome priming and assembly, MASLD-related lipotoxicity and fibrogenesis, podocyte and tubular injury, endothelial nitric oxide synthase uncoupling, AGE-RAGE signaling, and thrombo-inflammatory vascular injury. These pathways explain why biological vulnerability may persist even when conventional clinical parameters appear adequately controlled. We also examine the role of translational biomarkers and simple clinical indices, including TyG-derived indices, adiposity markers, hepatic steatosis and fibrosis scores, albuminuria, eGFR, and lipid-related markers, as accessible windows into active biological pathways. Finally, we review how contemporary therapeutic strategies may modulate selected components of this residual-risk network. A pathway-centered interpretation of T2D may support more precise residual-risk phenotyping and help move cardiometabolic care beyond isolated target control toward mechanism-based prevention. This review further links these mechanisms to the contemporary cardiovascular–kidney–metabolic (CKM) framework, as defined by the 2026 AHA/ACC/ADA/ASN CKM Guideline, and disaggregates the underlying molecular network into organ-specific pathway cascades that make the causal relationships between metabolic, inflammatory, hepatic, renal, and vascular injury more explicit.


  • Open Access

    Artificial Intelligence in Non-Insulin-Treated Type 2 Diabetes: From Reactive Management to Anticipatory Care

    by Antonio Maria Labate, Elena Cimino, Laura Giacomelli, Stefano Ettori, Oladayo Adigun Oladeji, Barbara Agosti

    Type 2 diabetes mellitus is a highly prevalent, heterogeneous, and progressive chronic disease. In a large proportion of patients, management is based for many years on lifestyle intervention and non-insulin glucose-lowering therapies. This long pre-insulin phase represents a crucial clinical window, in which timely recognition of metabolic deterioration, therapeutic inertia, treatment response, and individual risk trajectories may substantially influence long-term outcomes. However, routine care is still frequently based on intermittent assessments, delayed treatment adaptation, and limited integration of clinical, biochemical, behavioral, and digital data. Artificial intelligence may offer a clinically relevant opportunity to move from reactive management to anticipatory care in non-insulin-treated type 2 diabetes. Rather than replacing clinical judgment or automating treatment decisions, artificial intelligence can support clinicians by identifying hidden patterns, predicting metabolic worsening, stratifying risk, improving the interpretation of glucose data, and personalizing follow-up intensity and therapeutic timing. In this setting, its most meaningful role may be to reduce the silent interval between early deterioration and clinical action. This structured narrative review discusses the rationale, current applications, near-future scenarios, and implementation barriers of artificial intelligence in non-insulin-treated type 2 diabetes. Particular attention is given to advanced interpretation of glycemic data, clinical decision support, prediction of treatment failure, remote monitoring, and the potential integration of multidimensional data into more precise and timely care pathways. The review also emphasizes the need for explainable, clinically validated, equitable, and ethically governed artificial intelligence tools that can be realistically embedded into everyday diabetology practice.

  • Open Access

    Molecular Pathways of Cardiometabolic Residual Risk in Type 2 Diabetes: Insulin Resistance, Metaflammation, and Liver-Kidney-Vascular Crosstalk

    by Antonio Maria Labate, Elena Cimino, Laura Giacomelli, Stefano Ettori, Oladayo Adigun Oladeji, Barbara Agosti

    Cardiometabolic residual risk in type 2 diabetes mellitus (T2D) persists despite major advances in glucose-lowering therapy, lipid management, blood pressure control, weight reduction, and organ-protective strategies. This residual burden should not be interpreted solely as the consequence of incomplete achievement of conventional therapeutic targets, but rather as the clinical expression of persistent molecular activity involving multiple interconnected organs and pathways. Insulin resistance, metaflammation, oxidative stress, mitochondrial dysfunction, lipotoxicity, endothelial impairment, hepatic metabolic dysregulation, renal inflammation, fibrotic remodeling, and metabolic memory interact within a dynamic network linking adipose tissue, liver, kidney, immune cells, and vasculature. In this review, we discuss the biochemical and molecular drivers of cardiometabolic residual risk in T2D, with particular emphasis on impaired insulin receptor substrate/PI3K/Akt signaling, stress-kinase activation, NLRP3 inflammasome priming and assembly, MASLD-related lipotoxicity and fibrogenesis, podocyte and tubular injury, endothelial nitric oxide synthase uncoupling, AGE-RAGE signaling, and thrombo-inflammatory vascular injury. These pathways explain why biological vulnerability may persist even when conventional clinical parameters appear adequately controlled. We also examine the role of translational biomarkers and simple clinical indices, including TyG-derived indices, adiposity markers, hepatic steatosis and fibrosis scores, albuminuria, eGFR, and lipid-related markers, as accessible windows into active biological pathways. Finally, we review how contemporary therapeutic strategies may modulate selected components of this residual-risk network. A pathway-centered interpretation of T2D may support more precise residual-risk phenotyping and help move cardiometabolic care beyond isolated target control toward mechanism-based prevention.

  • Open Access

    Effectiveness and Safety of the Intermittently Scanned Continuous Glucose Monitoring System FreeStyle Libre 2 in Patients with Type 2 Diabetes Treated with Basal Insulin or Oral Antidiabetic Drugs: An Observational, Retrospective Real-World Study

    by Matteo Conti, Giulia Massari, Elena Meneghini, Bernadetta Pasquino, Barbara Agosti, Federica Chinotti, Basilio Pintaudi, Angela Girelli, Federico Bertuzzi

    Intermittently Scanned Continuous Glucose Monitoring (isCGM) devices are increasingly being used in patients with type 2 diabetes mellitus (T2DM) on insulin therapy for their benefits regarding disease management. Evidence of isCGM use in patients with T2DM on basal or non-insulin therapy is lacking. This study aimed at assessing the efficacy and safety of isCGM in this population. This was an observational, retrospective, real-world study enrolling patients with T2DM who were starting the use of isCGM. Data from medical records (i.e., demographics, clinical characteristics, laboratory assessments, and isCGM metrics) were collected over three time periods (baseline, 3 and 6 months). The endpoints were glycated haemoglobin (HbA1c) changes and changes in isCGM metrics as defined by the International Consensus from baseline to 3 months and 6 months. Overall, 132 patients were included (69.5% male; mean age 68.2 ± 11.0 years; mean disease duration 19.0 ± 9.4 years; 79.7% on basal insulin ±non-insulin therapy; mean baseline HbA1c 8.1% ± 1.3%). The estimated mean change in HbA1c was statistically significant at three (−0.4 ± 1.0%; p = 0.003) and six months (−0.6 ± 1.3%; p < 0.0001). In conclusion, isCGM proved to be effective and safe in improving glycaemic control in patients with T2DM on basal insulin or non-insulin therapy.